FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3012203663> ?p ?o ?g. }

• W3012203663 abstract "Background: Agents that activate innate and adaptive immunity have the potential for transformative immunotherapeutic approach in cancer treatment. Recent evidence suggests that the induction of innate immunity via the activation of RIG-I pathway in tumor cells, as well as immune cells in the tumor microenvironment (TME), can produce type I Interferons and cytokines for the induction of adaptive immunity as well as tumor cell death, thereby synergizing antitumoral effects. We describe here the discovery of highly potent first-in-class nucleotide compounds as RIG-I agonists. Methods: Synthesis: Using published crystal structure of 5´ppp-dsRNA bound to RIG-I in conjunction with structure-guided drug design, a focused library of more than 100 nucleotide compounds was generated and evaluated in multiple assays: (i) RIG-I binding affinity: Differential scanning fluorimetry was used to screen compounds for determining binding affinity to RIG-I (ii) Induction of IRF3: Compounds were assessed for IRF3 induction in doses ranging from 1 ug/mL to 100 ug/mL, using wild-type- and RIG-I-knockout mouse RAW cells, as well as, THP-1 cells carrying lucia reporter gene under the control of ISG54 minimal promoter and lead compounds were identified; (iii) Induction of cytokines: Lead compounds @ 100ug/ml were further evaluated for the induction of IFN-β and other cytokines in PBMCs and mouse bone-marrow-derived dendritic cells (mBMDCs) by Luminex analysis; (iv) Induction of Interferon Stimulated Genes (ISGs): ISGs such as DDX58, IFIT1, IFIT12, and IFIT13 were assessed by quantitative RT-PCR following treatment of the compounds in THP1 cells, PBMCs, and mBMDCs; (v) Induction of apoptosis in CT26 colon carcinoma cells: For determining apoptotic activity, CT26 cells were treated with various concentrations of the lead compounds, pppdsRNA or vehicle control and the apoptotic activity was measured using Caspase-Glo® 3/7 Assay (Promega). (vi) Release of DAMPs in CT26 colon carcinoma cells: For evaluating release of ATP and HMGB1, CT26 cells were treated with various concentrations of the lead compounds and supernatants were tested for presence of ATP and HMGB1 by ELISA. Results: Through in vitro assays in conjunction with SAR studies, we have identified several potent and selective first-in-class nucleotide compounds as RIG-I agonists. Two lead nucleotide compounds, SB 1 and SB 2, activated RIG-I in a dose-dependent manner to induce IRF3 signaling pathway in various cells. SB 1 and 2 also showed potent in vitro antitumor activity in multiple cell lines via both RIG-I dependent apoptosis of tumor cells and through the induction of IFNs, ISGs, and other cytokines, along with the expression of PRRs and ISGs including DDX58 IFIT1, IFIT2, and IFIT3. Conclusion: Highly potent RIG-I agonists that show excellent selectivity in the induction of IFN, NF-KB, ISGs, and PRRs and apoptosis of tumor-derived cell lines have been identified. The lead nucleotide compounds are being advanced for preclinical studies for applications in immuno-oncology. Citation Format: Sreerupa Challa, Ireneusz Nowak, Geeta Meher, Rayomand Gimi, Seetharamaiyer Padmanabhan, Dillon Cleary, Leena Suppiah, Diane Schmidt, Sam Baskaran, Lakshmi Bhagat, Radhakrishnana Iyer. Discovery of novel first-in-class nucleotide analogs as RIG-I agonists for immuno-oncology [abstract]. In: Proceedings of the AACR Special Conference on Tumor Immunology and Immunotherapy; 2019 Nov 17-20; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2020;8(3 Suppl):Abstract nr B76." @default.
• W3012203663 created "2020-03-23" @default.
• W3012203663 creator A5019542010 @default.
• W3012203663 creator A5038341045 @default.
• W3012203663 creator A5047116783 @default.
• W3012203663 creator A5052249955 @default.
• W3012203663 creator A5052998408 @default.
• W3012203663 creator A5056974250 @default.
• W3012203663 creator A5066924463 @default.
• W3012203663 creator A5075420131 @default.
• W3012203663 creator A5079446245 @default.
• W3012203663 creator A5088062712 @default.
• W3012203663 creator A5091243257 @default.
• W3012203663 date "2020-03-01" @default.
• W3012203663 modified "2023-10-14" @default.
• W3012203663 title "Abstract B76: Discovery of novel first-in-class nucleotide analogs as RIG-I agonists for immuno-oncology" @default.
• W3012203663 doi "https://doi.org/10.1158/2326-6074.tumimm19-b76" @default.
• W3012203663 hasPublicationYear "2020" @default.
• W3012203663 type Work @default.
• W3012203663 sameAs 3012203663 @default.
• W3012203663 citedByCount "0" @default.
• W3012203663 crossrefType "proceedings-article" @default.
• W3012203663 hasAuthorship W3012203663A5019542010 @default.
• W3012203663 hasAuthorship W3012203663A5038341045 @default.
• W3012203663 hasAuthorship W3012203663A5047116783 @default.
• W3012203663 hasAuthorship W3012203663A5052249955 @default.
• W3012203663 hasAuthorship W3012203663A5052998408 @default.
• W3012203663 hasAuthorship W3012203663A5056974250 @default.
• W3012203663 hasAuthorship W3012203663A5066924463 @default.
• W3012203663 hasAuthorship W3012203663A5075420131 @default.
• W3012203663 hasAuthorship W3012203663A5079446245 @default.
• W3012203663 hasAuthorship W3012203663A5088062712 @default.
• W3012203663 hasAuthorship W3012203663A5091243257 @default.
• W3012203663 hasConcept C136449434 @default.
• W3012203663 hasConcept C153911025 @default.
• W3012203663 hasConcept C193419808 @default.
• W3012203663 hasConcept C203014093 @default.
• W3012203663 hasConcept C2776178377 @default.
• W3012203663 hasConcept C2776954689 @default.
• W3012203663 hasConcept C2777701055 @default.
• W3012203663 hasConcept C2780209191 @default.
• W3012203663 hasConcept C2780674031 @default.
• W3012203663 hasConcept C502942594 @default.
• W3012203663 hasConcept C86803240 @default.
• W3012203663 hasConcept C8891405 @default.
• W3012203663 hasConceptScore W3012203663C136449434 @default.
• W3012203663 hasConceptScore W3012203663C153911025 @default.
• W3012203663 hasConceptScore W3012203663C193419808 @default.
• W3012203663 hasConceptScore W3012203663C203014093 @default.
• W3012203663 hasConceptScore W3012203663C2776178377 @default.
• W3012203663 hasConceptScore W3012203663C2776954689 @default.
• W3012203663 hasConceptScore W3012203663C2777701055 @default.
• W3012203663 hasConceptScore W3012203663C2780209191 @default.
• W3012203663 hasConceptScore W3012203663C2780674031 @default.
• W3012203663 hasConceptScore W3012203663C502942594 @default.
• W3012203663 hasConceptScore W3012203663C86803240 @default.
• W3012203663 hasConceptScore W3012203663C8891405 @default.
• W3012203663 hasLocation W30122036631 @default.
• W3012203663 hasOpenAccess W3012203663 @default.
• W3012203663 hasPrimaryLocation W30122036631 @default.
• W3012203663 hasRelatedWork W13753268 @default.
• W3012203663 hasRelatedWork W19000303 @default.
• W3012203663 hasRelatedWork W25931554 @default.
• W3012203663 hasRelatedWork W35513613 @default.
• W3012203663 hasRelatedWork W36290674 @default.
• W3012203663 hasRelatedWork W36652119 @default.
• W3012203663 hasRelatedWork W38803104 @default.
• W3012203663 hasRelatedWork W38985206 @default.
• W3012203663 hasRelatedWork W6050890 @default.
• W3012203663 hasRelatedWork W7946148 @default.
• W3012203663 isParatext "false" @default.
• W3012203663 isRetracted "false" @default.
• W3012203663 magId "3012203663" @default.
• W3012203663 workType "article" @default.